Cell therapy is one of the most promising advances in modern cancer treatment. The basic concept involves collecting a patient’s own immune cells, genetically reprogramming them in the laboratory so they recognize cancer more effectively, and then infusing them back into the patient’s body. Once circulating, these enhanced immune cells are designed to seek out and destroy cancer cells while leaving healthy tissue largely untouched. The approach has already produced remarkable results in certain blood cancers, where engineered CAR T-cell therapies have driven durable remissions in patients who had exhausted conventional options. Translating that success to solid tumors, however, has proven far more difficult. Solid tumors build defensive microenvironments that suppress immune activity, physically exclude T cells and exhaust the cells that do manage to infiltrate. The new UChicago Medicine trial is designed specifically to confront those barriers, combining tumor recognition with engineered resistance to the immunosuppressive signals that tumors deploy.

The scientific foundation of the treatment differs in an important way from existing CAR T-cell platforms. Conventional CAR T cells use engineered synthetic receptors that recognize proteins displayed on the surface of cancer cells. The UChicago team, by contrast, is using specially engineered T-cell receptors, the natural antigen-recognition machinery of the immune system, which allow immune cells to detect protein fragments presented from inside cancer cells. This distinction matters enormously for the range of cancers that can be targeted. Many of the most attractive tumor-associated proteins are not displayed on the cell surface but are processed internally and presented on major histocompatibility complex molecules, invisible to CAR constructs but perfectly visible to a properly directed T-cell receptor. By exploiting this intracellular surveillance pathway, the researchers dramatically expand the universe of tumors that engineered cell therapies might plausibly attack.

Richard Koya, MD, PhD, Professor of Obstetrics and Gynecology at UChicago Medicine, is the scientific investigator who developed the treatment and designed the clinical trial on the basis of many years of laboratory research. He framed the strategy as an extension of the immune system’s own logic. The team, he explained, is using the same natural process the immune system relies on to fight infections, but redirecting it to attack cancer. The stated goal is to create immune cells that can recognize cancer more effectively, survive longer and continue fighting the disease over time. That emphasis on persistence reflects a central lesson of immunotherapy research: engineered cells that fade quickly or become dysfunctional inside tumors rarely produce lasting benefit, whereas cells that endure and form immune memory may hold tumors in check long after the initial infusion.

The treatment protocol unfolds in several carefully sequenced stages. Doctors will first collect a patient’s white blood cells through a process similar to blood donation. Patients will then receive the chemotherapy drug decitabine, chosen for a specific biological effect: it increases the production of a cancer protein called NY-ESO-1, a target found in many tumors but absent from healthy adult tissues. This priming step is intended to make tumor cells more visible to the engineered immune cells that will follow. In the laboratory, researchers will then genetically engineer the patient’s immune cells with two critical features. The first is a T-cell receptor that recognizes NY-ESO-1, equipping the cells to identify and attack cancer. The second is a genetic modification that blocks TGF-beta, a signaling molecule that normally suppresses immune responses and contributes to T-cell exhaustion inside tumors, one of the principal reasons cell therapies have underperformed against solid disease.

Once the engineering is complete, the enhanced immune cells will be infused back into the patient through an intravenous line, much like a blood transfusion. Patients will also receive a low dose of interleukin-2, an immune-boosting drug that helps the engineered T cells multiply and remain active after they enter the body. The investigators plan to infuse approximately one billion engineered T cells into each patient, a dose intended to generate a powerful and durable immune response against cancers that currently have few effective treatment options. Researchers believe this combination, antigen targeting, resistance to suppressive signaling and cytokine support, could produce a stronger and longer-lasting immune response because it addresses one of the biggest challenges in solid tumor treatment: the hostile tumor environment that often weakens cancer-fighting immune cells before they can eliminate the tumor. By engineering T cells to resist signals such as TGF-beta, the team hopes the cells will persist longer, develop lasting immune memory and continue attacking tumors over time.

The trial’s design and execution are notable for their institutional provenance. This is an investigator-initiated clinical trial, meaning the treatment was conceived and developed by University of Chicago researchers rather than a commercial sponsor. The UChicago Medicine Comprehensive Cancer Center, which operates one of the nation’s largest cancer clinical trials programs, has extensive experience translating laboratory discoveries into early-stage clinical studies, and that infrastructure is now being applied to a therapy the institution controls end to end. Critically, the engineered cells will be produced in UChicago Medicine’s Good Manufacturing Practices facility, a highly specialized laboratory that meets strict federal standards for producing cell therapies. On-site manufacturing allows researchers to oversee every step of the process, maintain quality control and accelerate the translation of discoveries from the laboratory to patients, a capability that very few academic medical centers possess.

Koya emphasized the strategic value of that capability. Very few academic medical centers, he noted, have the ability to manufacture personalized cell therapies entirely on-site, and he described the arrangement as giving the team tremendous flexibility to rapidly test new ideas and move promising treatments to patients. That flexibility is particularly consequential in the fast-moving field of cellular immunotherapy, where iterative design changes, new receptor constructs and combination strategies often emerge faster than commercial pipelines can accommodate. An academic GMP facility effectively shortens the distance between a laboratory observation and a patient-ready product, allowing investigators to refine the therapy across successive cohorts in ways that industry-sponsored trials, bound by fixed manufacturing contracts and regulatory timelines, often cannot.

The Phase 1/2A trial will evaluate the experimental therapy in a small group of patients with metastatic ovarian cancer, soft tissue sarcoma, bladder cancer, prostate cancer, breast cancer, melanoma or non-small cell lung cancer, all cancers that form solid tumors and all diseases in which effective options narrow sharply once the disease has spread. Beginning in October 2026, screening for eligible patients will take place at UChicago Medicine locations in Hyde Park, New Lenox, Harvey, Flossmoor, Calumet City and Tinley Park in Illinois, and Crown Point in Indiana, with treatment taking place at the main campus in Hyde Park. UChicago Medicine oncologist Daniel Olson, MD, Assistant Professor of Medicine, is the clinical investigator overseeing the trial, while Thinle Chodon, MD, PhD, research professor, is overseeing production of the engineered cells in the institution’s GMP facility. The division of roles between clinical leadership and manufacturing oversight reflects the operational complexity of personalized cell therapy, in which each patient’s product is a bespoke biological medicine.

The launch arrives as UChicago Medicine continues to expand its cancer care and research enterprise. The institution was among the first medical centers in the country to offer FDA-approved CAR T-cell therapy for adults and children with certain blood cancers, and more recently became one of the first centers to provide tumor-infiltrating lymphocyte therapy for advanced melanoma, establishing a track record at the leading edge of cellular immunology. In April 2027, UChicago Medicine will open the AbbVie Foundation Cancer Pavilion, Chicago’s first freestanding cancer pavilion, intended to bring advanced diagnostics, innovative treatments, translational discoveries and comprehensive support services to patients and the surrounding community. For patients with advanced solid tumors, the new trial offers something more immediate: a chance to access an immunotherapy approach that targets hidden tumor proteins, resists the suppressive forces of the tumor microenvironment and is produced by the same institution treating them, a model of academic self-reliance that may shape how the next generation of cancer cell therapies reaches the clinic.

Subject of Research: A Phase 1/2A clinical trial of an investigator-developed engineered T-cell receptor therapy targeting NY-ESO-1 for advanced solid tumors

Article Title: UChicago Medicine launches homegrown cell therapy for advanced solid tumors

Article References: UChicago Medicine launches homegrown cell therapy for advanced solid tumors. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cell therapy, T-cell receptor, solid tumors, NY-ESO-1, TGF-beta, ovarian cancer, CAR T-cell therapy, GMP manufacturing, clinical trial, immunotherapy, decitabine, interleukin-2

A team led by Franka Buytenhuijs, Cornelia Tune, Thomas C. Smits, Andrea Schampel, Lisa-Kristin Schierloh, René Pagel, Jürgen Westermann, and Johannes Textor set out to dissect how the T cell receptor repertoire is distributed across the major compartments of the mouse spleen. The spleen is an ideal testing ground for this question because it contains clearly demarcated regions: the T cell zones, where T cells normally congregate; the B cell zones, which are dominated by B lymphocytes but normally contain a small number of T cells; and the germinal centers, specialized structures within B cell zones where antibody affinity maturation takes place and where T helper cells provide critical support to B cells.

The researchers’ strategy relied on precision microdissection. Rather than analyzing whole spleens, they physically separated T cell zones, B cell zones, and germinal centers from both naïve mice and mice that had been immunized with a complex antigen. From each compartment they extracted DNA and sequenced the complementarity-determining region 3 of the T cell receptor beta chain, abbreviated CDR3β. This short stretch of amino acids is the most variable part of the receptor and serves as a practical fingerprint of clonal identity, allowing the team to track individual T cell clones and measure how abundant each clone was in each splenic neighborhood.

The initial comparison produced a striking result: the receptor repertoires of the three compartments looked substantially different from one another. At face value, this seemed to support the idea that receptor-intrinsic features guide T cell localization. But the team did not stop at the descriptive level. They built statistical models that asked a more demanding question: could the observed differences be explained without invoking any special homing properties of particular receptors, simply by accounting for how big each compartment is and how fast the cells within it are dividing?

The answer, in most cases, was yes. During the steady state, before any immune challenge, the handful of T cells found in B cell zones turned out to strongly resemble random subsets of the T cell zone repertoire. In other words, the T cells that stray into B cell territory appear to be an unbiased sample of the broader T cell population rather than a select subset with distinctive receptors. Once the effect of compartment size was factored into the analysis, the apparent compositional differences between T cell zones and B cell zones largely evaporated.

Immunization changed the picture in a dynamic and informative way. After the mice were challenged with antigen, expanded clones began to appear in the T cell zones by day three, marking the onset of the proliferative response. As the response progressed, these expanded clones later shifted their dominance toward the B cell zones, consistent with the migration of activated T helper cells to the sites where they assist B cells. Germinal centers harbored clones that had expanded even further, and these clones showed a tendency to group into clusters with high sequence similarity, reflecting the family relationships of proliferating T cells that had descended from common precursors.

To make sense of these temporal patterns, the researchers turned to a classical mathematical framework: the Galton-Watson branching process, a stochastic model of population growth in which each cell independently divides or fails to divide according to fixed probabilities. When they fitted this model of T cell proliferation to their data, it explained the repertoire differences observed during the immune response remarkably well. The implication is provocative: the central factor shaping the spatial differences in the splenic T cell receptor repertoire may simply be how much the cells in each compartment have proliferated, not any receptor-sequence-dependent trafficking rule.

The team also examined whether specific structural features of the receptor, beyond clonal identity, correlated with compartmental localization. Two features stood out initially: the length of the CDR3β region and the closeness of the receptor sequence to its germline configuration, a measure of how much the receptor has diverged from the inherited template. Both features showed more pronounced differences between compartments in the raw data, hinting that they might influence localization. Yet here again the models of random distribution and proliferation accounted for these differences almost entirely. Apparent sequence-based patterns dissolved once the confounding effects of compartment size and clonal expansion were explicitly modeled.

Taken together, the findings suggest that splenic T cell receptor repertoires are shaped predominantly by compartment size and proliferation rates rather than by T cell receptor sequence features. This conclusion carries practical consequences for the rapidly growing field of spatial immune profiling. As technologies for sequencing receptors from anatomically defined regions proliferate, researchers increasingly report spatial differences in repertoire composition and interpret them as evidence of receptor-guided positioning. This study demonstrates that such interpretations are unsafe without quantitative controls: a repertoire difference between two compartments can arise purely because one compartment is small, or because the cells within it have undergone more rounds of division, without any receptor-intrinsic homing behavior at all.

The authors argue that a quantitative assessment of T cell receptor repertoire dynamics across heterogeneous spatial compartments during an immune response is only possible when the effects of compartment size and proliferation are explicitly accounted for. Their work provides a template for how to do this, combining microdissection, high-throughput CDR3β sequencing, and mechanistic models of clonal expansion. For immunologists studying how the body marshals its T cell forces during infection or vaccination, the message is clear: before attributing spatial repertoire patterns to the sequences of the receptors themselves, one must first ask whether simple arithmetic of anatomy and cell division can explain the observation. In the mouse spleen, at least, it largely can.

Subject of Research: Spatial distribution of the splenic T cell receptor repertoire during immune responses in mice

Article Title: How compartmentalization and proliferation shape the splenic T cell repertoire during an immune response to a complex antigen in mice

Article References: Buytenhuijs, F., Tune, C., Smits, T. C., Schampel, A., Schierloh, L.-K., Pagel, R., Westermann, J., & Textor, J. (2026). How compartmentalization and proliferation shape the splenic T cell repertoire during an immune response to a complex antigen in mice. PLOS Computational Biology, 22(10), e1014859. https://doi.org/10.1371/journal.pcbi.1014859

Image Credits: AI Generated

DOI: 10.1371/journal.pcbi.1014859

Keywords: T cell receptor, repertoire sequencing, spleen, germinal centers, compartmentalization, clonal proliferation, Galton-Watson model, CDR3β, immunization, computational biology, spatial immunology, mouse model

Much of modern cardioimmunology has been built on the premise that inflammation matters, but that its specificity does not. That premise has produced real clinical wins. Large trials of canakinumab, an interleukin-1beta antibody, demonstrated that blunting innate inflammation reduces cardiovascular events in patients with atherosclerotic disease, and low-dose colchicine has entered routine secondary prevention. More recently, randomized phase 2 trials of low-dose interleukin-2, intended to expand regulatory T cells, have tested whether boosting immune tolerance can calm vascular and myocardial inflammation after acute coronary syndromes. Imaging probes that track CCR2-positive monocytes into the injured heart have given clinicians a window onto the inflammatory infiltrate. Yet all of these approaches share a fundamental limitation: they target broad inflammatory programs rather than the antigen-specific lymphocytes that may be orchestrating, sustaining or sometimes protecting the myocardium.

The evidence that antigen-specific T cell responses to the heart exist is not new. In the late 1980s, researchers showed that immunizing genetically predisposed mice with cardiac myosin, the molecular motor of the heartbeat, induced autoimmune myocarditis, and subsequent work established that the disease was T cell mediated. The myocarditis-inducing epitope of cardiac myosin heavy chain alpha was mapped and shown to bind stably to major histocompatibility complex class II molecules on antigen-presenting cells. Decades later, the clinical relevance of these findings crystallized around a dramatic iatrogenic disease: myocarditis triggered by immune checkpoint inhibitors, the cancer therapies that unleash T cells against tumors. Independent teams showed that T cells specific for alpha-myosin and other cardiac myosin epitopes expand in patients with checkpoint-inhibitor myocarditis, providing the clearest demonstration yet that a heart antigen can drive fulminant human cardiac autoimmunity.

Why would the immune system be primed against its own heart? Part of the answer lies in central tolerance. The thymus deletes T cells that react strongly with self-proteins it displays, but the gene encoding alpha-myosin heavy chain, the dominant cardiac contractile protein, is expressed poorly or not at all in thymic medullary epithelial cells. This gap in thymic tolerance, demonstrated in both mice and humans, leaves a reservoir of T cells capable of recognizing the heart’s most abundant autoantigen. Peripheral mechanisms normally keep these cells in check, but injury can break the truce. When cardiomyocytes die, as in a heart attack or viral infection, cardiac proteins are released, taken up by dendritic cells and presented to T cells in a pro-inflammatory context, a process known as cross-priming. Molecular mimicry adds another route: microbial peptides that resemble cardiac epitopes, whether from group A streptococci in rheumatic heart disease or from the gut microbiota in experimental inflammatory cardiomyopathy, can activate T cells that then attack the heart.

The catalogue of validated cardiac antigens remains short but instructive. Cardiac myosin heavy chain alpha dominates, with defined class II-restricted epitopes and, more recently, identified class I epitopes for CD8 T cells. Cardiac troponin I is a second major player; unlike troponin T, it induces severe autoimmune inflammation in the myocardium when used to immunize mice, and autoantibodies against it correlate with outcomes after infarction. The beta-1 adrenergic receptor, long known as a target of functional autoantibodies in dilated cardiomyopathy, also contains epitopes that elicit T cell responses of varying pathogenicity. Additional candidates include the adenine nucleotide translocator, SERCA2a, the calcium pump of the sarcoplasmic reticulum, and branched-chain alpha-ketoacid dehydrogenase kinase. Beyond classical self-antigens, modified self can be antigenic: isolevuglandin-modified cardiac proteins drive CD4 T cell activation and dysfunction in the heart, and citrullination of myofilament proteins may reveal cryptic epitopes, a mechanism familiar from rheumatoid arthritis.

What these antigens share, and what the review proposes as a working framework, is a combination of abundance, cardiac enrichment and presentability. The heart is overwhelmingly composed of cardiomyocytes packed with contractile machinery, so its proteome is dominated by sarcomeric proteins that are scarce elsewhere. Proteomic atlases of the human heart, from quantitative maps of ventricular and atrial regions to single-cell and spatial transcriptomics of cardiac niches, now provide the raw material for predicting which proteins are sufficiently heart-enriched and sufficiently abundant to serve as targets. The critical filter is immunological: a candidate antigen must actually be processed and presented on MHC molecules. Strikingly, myosin-class II complexes have been detected in normal myocardium even before any injury, suggesting that the heart constitutively displays its own dominant antigen and that disease depends on context rather than mere exposure.

Not all heart-directed T cell responses are destructive, and this nuance may prove therapeutically decisive. Myocardial infarction has been shown to trigger cardioprotective, antigen-specific T helper responses, and a unique population of cardiac regulatory T cells potentiates protection after ischemic injury. In atherosclerosis, T cells reactive against apolipoprotein B begin as protective regulatory cells and can lose that identity as disease progresses, converting from guardians to drivers of plaque inflammation. Regulatory T cells that recognize troponin or myosin epitopes modulate healing after infarction, and the myocardial milieu itself favors local differentiation of regulatory T cells. The same antigen, in other words, can support repair or pathology depending on the functional polarization of the T cells that recognize it, a duality that any antigen-specific intervention must navigate carefully.

Turning this biology into medicine will require tools to see the relevant T cells, and such tools are finally emerging. MHC multimers loaded with defined cardiac peptides allow direct staining and isolation of antigen-specific T cells from blood and tissue. Single-cell T cell receptor sequencing, applied to paired atherosclerotic plaques and blood, has revealed expanded effector clones with autoimmune features, and comparable approaches have mapped the immune response in checkpoint-inhibitor myocarditis across heart, blood and tumor. Curated databases of pathology-associated TCR sequences, machine-learning methods for inferring TCR specificity, and CRISPR-based orthotopic TCR replacement for validating candidate receptors together form a toolkit that the review positions as the foundation for the next decade of mechanistic work. Transgenic mice carrying myosin-specific T cell receptors, first generated more than a decade ago, continue to illuminate how CD4 and CD8 subsets contribute to myocarditis and its progression to dilated cardiomyopathy.

The therapeutic horizon is equally provocative. Engineered T cells targeting fibroblast activation protein have been shown in preclinical studies to blunt cardiac fibrosis, including chimeric antigen receptor T cells produced in vivo via mRNA delivery, hinting at a future where the antigen-specific arm of immunity is redirected rather than suppressed. Conversely, costimulation blockade with abatacept has been deployed as rescue therapy for severe checkpoint-inhibitor myocarditis, a rational application of the two-signal model of T cell activation to a fulminant, antigen-driven disease. Preventive vaccine-style approaches that tolerize against cardiac autoantigens have shown promise in experimental heart failure. None of these strategies can be designed rationally, the review concludes, without a complete inventory of cardiac antigens and the T cell repertoires that recognize them. By fusing cardiac proteomics with immunopeptidomics, the systematic analysis of peptides displayed on MHC molecules, and with T cell receptor tracking from model organisms to patients, the field aims to convert heart-specific immunity from a scattered collection of observations into a defined, druggable axis of cardiovascular medicine.

Subject of Research: Antigen-specific T cell responses to cardiac proteins in myocarditis, myocardial infarction and heart failure

Article Title: Heart-specific T cell responses: from antigens to disease mechanisms

Article References: Campos Ramos, G. (2026). Heart-specific T cell responses: from antigens to disease mechanisms. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-026-01356-x

Image Credits: AI Generated

DOI: 10.1038/s41569-026-01356-x

Keywords: T cells, cardiac antigens, myocarditis, myocardial infarction, heart failure, autoimmunity, MHC, immunopeptidomics, cardioimmunology, regulatory T cells, immune checkpoint inhibitors, T cell receptor

The research focuses on a family of CD4-positive helper T cells known as Th17 cells, which have occupied an ambiguous position in cystic fibrosis immunology for over a decade. Elevated levels of interleukin-17, the signature cytokine of this lineage, were initially interpreted as a hallmark of pathology, since IL-17 drives neutrophil recruitment and tissue-destructive inflammation. Later work complicated that picture by showing that Th17 cells are functionally heterogeneous. Conventional Th17 cells, which co-produce IL-17 alongside the anti-inflammatory cytokine IL-10 and the epithelial-supporting IL-22, actually promote mucosal homeostasis and barrier integrity. By contrast, a distinct pro-inflammatory population, termed Th1/17 for its co-expression of interferon-gamma and IL-17 in the absence of IL-10, has been implicated in chronic inflammatory diseases ranging from multiple sclerosis to Crohn’s disease. Which of these faces Th17 presents in the cystic fibrosis lung remained an open question.

To resolve it, the team analysed T cells isolated from explanted lungs and blood of people with cystic fibrosis, alongside non-CF lung tissue and healthy donor blood. Using high-dimensional flow cytometry and unsupervised clustering based on chemokine receptor expression, they identified two pathogenic subsets, CCR5-positive Th1/17 cells and pro-inflammatory CCR5-positive Th17 cells, that were markedly enriched in cystic fibrosis lungs compared with both patient blood and non-CF lungs. Critically, this enrichment was not a general feature of the disease. The pathogenic subsets expanded selectively in lungs chronically colonized by Pseudomonas aeruginosa, irrespective of whether other pathogens such as Staphylococcus aureus were also present. In Pseudomonas-negative patients, protective conventional Th17 cells predominated instead, pointing to the bacterium itself as the upstream driver of the pathological shift.

The functional consequences of this shift were striking. In an air-liquid interface model of primary human bronchial epithelium, a laboratory system that recapitulates the differentiated, ciliated airway lining, activated Th1/17 and pro-inflammatory Th17 cells caused extensive disruption of epithelial integrity. Immunofluorescence staining for zonula occludens-1, a core component of tight junctions, revealed discontinuous, fragmented junctional patterns in cultures exposed to these subsets, while conventional Th17 cells left the barrier largely intact. Quantitative artificial intelligence-assisted image analysis confirmed the selective loss of junctional continuity. The pathogenic subsets also provoked a significantly stronger inflammatory response from epithelial cells, which released elevated amounts of cytokines and chemokines including IL-8, IL-6, CCL20 and RANTES, molecules that in turn recruit further immune cells to the airway wall.

Transcriptomic profiling by RNA sequencing deepened the picture. Pulmonary Th1/17 and pro-inflammatory Th17 cells from Pseudomonas-infected cystic fibrosis lungs displayed a distinctive signature of 210 upregulated and 40 downregulated genes compared with the same subsets in blood and non-CF lungs. Gene set enrichment analysis showed that lung-resident pathogenic cells upregulated 21 pathways linked to bacterial response, inflammation and tissue remodelling, with high-ranking genes including PPARG, CEBPD and IRAK2, transcriptional regulators known to shape Th17 differentiation and function. Peripheral counterparts of the same subsets showed a largely repressed programme, indicating that the lung environment itself actively reconfigures these cells rather than merely recruiting pre-formed effectors from the circulation.

T cell receptor sequencing added a crucial layer of evidence. The researchers found a significant expansion of private clonotypes, receptor sequences unique to individual patients, within cystic fibrosis lungs, accounting for 45.8 percent of the Th1/17 repertoire compared with roughly 22 percent in non-CF lungs. Among the most expanded clonotypes, some were shared between Th1/17 and pro-inflammatory Th17 cells but minimally represented in Th1 or conventional Th17 populations, suggesting a common antigenic experience driving functional convergence. Partial overlap between the receptor repertoires of pathogenic subsets and conventional Th17 cells, but not Th1 cells, provided a molecular fingerprint of lineage relationships that the team then tested experimentally.

That experimental work centred on dendritic cells, the antigen-presenting sentinels that instruct T cell fate. The team exposed human monocyte-derived dendritic cells to 26 clinical Pseudomonas aeruginosa strains isolated longitudinally from Danish cystic fibrosis patients, spanning early isolates taken at disease onset and late isolates collected after years of chronic colonization. Late strains were internalized more efficiently and persisted longer inside dendritic cells than the reference laboratory strain PAO1. More importantly, clinical isolates skewed the dendritic cell cytokine output toward a polarizing cocktail of IL-1β and IL-23, the two cytokines known to drive interferon-gamma-producing Th17 differentiation, while relatively suppressing IL-12, the canonical Th1-polarizing signal. IL-1β secretion correlated with intracellular bacterial persistence, and clinical strains also triggered strong release of CCL20, the chemokine that recruits CCR6-positive Th17 cells to sites of infection.

In antigen-specific co-culture assays, the researchers then demonstrated that conventional Th17 cells, not Th1 cells, are the precursors of the pathogenic populations. After ten days of co-culture with Pseudomonas-infected dendritic cells, sorted conventional Th17 cells acquired robust interferon-gamma and IL-17 co-expression, whereas Th1 cells never converted. Unexpectedly, early clinical isolates lacking the classic adaptations of chronic infection, such as reduced motility and biofilm formation, were at least as effective as late isolates at inducing this conversion, and some strains exceeded the levels seen with PAO1. The reprogramming extended to transcription factors: converted cells upregulated C/EBPδ and PPARγ, and in some cases BATF3, mirroring the profile of lung-resident pathogenic Th17 cells from patients. This indicates that the immunostimulatory virulence determinants responsible are present from the earliest stages of colonization and retained throughout bacterial adaptation to the cystic fibrosis lung.

The study thereby rewrites a long-standing paradigm. Adaptive immune dysfunction in cystic fibrosis was widely assumed to emerge only in late-stage disease, but the new data show that Pseudomonas aeruginosa can corrupt protective Th17 immunity from the moment it establishes infection, creating a self-sustaining immunopathological loop in which reprogrammed T cells damage the epithelium, epithelial cells release chemokines that recruit more Th17 cells, and the resulting inflammation further impairs bacterial clearance. The findings carry direct therapeutic implications. IL-1 receptor blockade with anakinra has already been shown to mitigate Pseudomonas-driven airway inflammation in cystic fibrosis, and IL-23 inhibitors are clinically established in other chronic inflammatory diseases, although safety concerns about prolonged IL-1β blockade and the need to preserve protective mucosal immunity remain. The authors caution that their lung cohort reflects advanced disease and that the specific bacterial or host antigens driving the T cell skewing are still unknown. Even so, selectively depleting Th1/17 and pro-inflammatory Th17 cells, or blocking their generation from conventional Th17 precursors, now stands as a credible precision immunomodulatory strategy, one that could address the inflammation that persists even in patients receiving CFTR modulator therapy.

Subject of Research: Pseudomonas aeruginosa-driven reprogramming of Th17 cells in cystic fibrosis lung immunopathology

Article Title: Pseudomonas aeruginosa induces the generation of pathogenic IFNγ+Th17 cells that promote lung damage and chronic inflammation in cystic fibrosis

Article References: Dusetti, I., Conte, G., Chiara, M., Puccio, S., Guidone, D., Ricciardelli, E., Cibella, J., Ronzio, M., Dolfini, D., Rossi, E., Landini, P., Ascagni, M., Orlandi, R., Damarco, F., Palleschi, A., Gramegna, A., Blasi, F., Lugli, E., Galietta, L. J., … Paroni, M. (2026). Pseudomonas aeruginosa induces the generation of pathogenic IFNγ+Th17 cells that promote lung damage and chronic inflammation in cystic fibrosis. Nature Microbiology. https://doi.org/10.1038/s41564-026-02469-2

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02469-2

Keywords: cystic fibrosis, Pseudomonas aeruginosa, Th17 cells, interferon-gamma, dendritic cells, IL-23, IL-1β, epithelial barrier, T cell receptor, mucosal immunity, chronic inflammation, immunotherapy

The adaptive immune system depends on an extraordinary diversity of antigen receptors. T cells and B cells generate their receptors through a process called V(D)J recombination, in which variable, diversity, and joining gene segments are randomly stitched together, with additional nucleotide insertions and deletions at the junctions. This combinatorial and junctional diversity, together with the pairing of heavy and light chains in B cells and alpha and beta chains in T cells, allows the immune system to recognize an almost limitless range of pathogens. The composition of these repertoires reflects immune development, tissue microenvironment, antigen exposure history, and disease status, making their systematic characterization essential for understanding immune surveillance and tissue-specific immune regulation.

Previous studies of the porcine immune repertoire relied largely on bulk sequencing, which averages signals across mixed cell populations and offers limited resolution for dissecting cellular heterogeneity and lineage relationships. Although high-throughput repertoire sequencing had revealed preferential V(D)J gene usage and clonotype expansion in pigs, those studies generally lacked simultaneous transcriptomic information, meaning receptor features could not be directly linked to immune cell identity, functional state, or tissue location. The new work closes that gap by integrating single-cell RNA sequencing with paired V(D)J repertoire sequencing at single-cell resolution.

To build the atlas, the team, led by researchers from Sun Yat-Sen University, the Harbin Veterinary Research Institute, and Beijing BestopCell, sampled three clinically healthy, 14-day-old male DLY crossbred piglets weighing approximately 4 kilograms. The animals were screened by RT-qPCR for major swine pathogens, including porcine epidemic diarrhea virus, transmissible gastroenteritis virus, porcine deltacoronavirus, rotavirus, porcine reproductive and respiratory syndrome virus, and African swine fever virus, and all tests were negative. None of the piglets had been vaccinated, ensuring that the recorded immune landscape reflected a true physiological baseline rather than an antigen-driven response.

The researchers collected eleven immune-associated tissues spanning lymphoid, mucosal, and circulatory compartments: peripheral blood, spleen, thymus, tonsil, lung, bone marrow, intestinal lymph node, bronchial lymph node, Peyer’s patch, and the mucous membranes of the ileum and jejunum. After careful tissue dissociation, debris removal, and quality control filtering that eliminated 22,141 low-quality cells, a total of 71,731 cells were retained for analysis. Sequencing was performed on an MGI DNBSEQ-T7 platform, and the data were processed with the Seurat and scRepertoire frameworks against the Sscrofa11.1 reference genome.

The cellular inventory revealed the expected cast of immune players: T cells, B cells, natural killer cells, plasma cells, monocytes, and neutrophils, alongside structural endothelial, epithelial, and fibroblast populations. Cell-type identities were anchored to canonical markers, with B cells expressing CD19, MS4A1, and CD79A; T cells expressing CD3D, CD3E, and CD3G; and plasma cells marked by MZB1 and CD38. Reclustering resolved five major B-cell subpopulations, including naive, memory, germinal center, plasma, and cycling plasma cells, and nine T-cell subpopulations ranging from naive and memory CD4 and CD8 subsets to regulatory T cells, cycling T cells, and double-positive CD4-CD8 cells. The distribution of these subsets varied sharply by tissue: lymphoid organs were dominated by adaptive immune cells, mucosal tissues carried more epithelial and innate components, and double-positive T cells concentrated in thymic compartments, consistent with thymocyte development.

On the repertoire side, the team identified 3,275 BCR clones and 13,431 TCR clones. Both receptor classes showed strongly biased, non-random V(D)J gene usage. The five most frequent BCR V genes, including IGHV1S201 and IGHV1-1501, together accounted for 39.41 percent of total V-gene usage, while the IGHJ501 segment alone represented 44.95 percent of J-gene usage. In the TCR repertoire, segments such as TRAV15 and TRBV20-201 were preferentially enriched, alongside dominant TRBJ genes. Complementarity-determining region 3 (CDR3) lengths, the hypervariable loops that contact antigen, fell into narrow, conserved intervals: 10 to 12 and 29 to 31 amino acids for BCRs, and 12 to 14 and 26 to 28 for TCRs, with these patterns remaining stable across tissues, reflecting structural constraints on receptor generation.

Cross-tissue analyses revealed a striking asymmetry between humoral and cellular immunity. BCR clonotypes were shared far more extensively between tissues, particularly among Peyer’s patch, intestinal lymph node, ileum mucosa, and peripheral blood, whereas TCR clones showed higher tissue specificity, with the strongest sharing between peripheral blood and spleen. Because the samples came from unchallenged animals, the authors interpret this multi-organ sharing not as antigen-driven expansion but as a manifestation of intrinsic V(D)J recombination bias, in which certain gene combinations and CDR3 lengths are preferentially generated, producing ‘public-like’ clonotypes that coexist systemically. The team also notes that B cells routinely recirculate through blood and lymph, while T cells tend toward tissue residency, though their homing-receptor analysis did not show a statistically significant difference between the two lineages, leaving the mechanistic basis open.

Mapping receptor sequences back onto the single-cell transcriptomic map through matched cell barcodes linked clonal dynamics to cell state. BCRs concentrated in plasma cell and cycling plasma cell populations, and the plasma cell subset showed enriched use of IGHA and IGHG heavy chains with elevated IGHG subclass diversity, hallmarks of antibody maturation and class-switch recombination. Immunoglobulin M accounted for more than half of heavy-chain usage in each B-cell cluster, while kappa and lambda light-chain preferences differed between subsets. TCRs were concentrated in naive CD4, naive CD8, regulatory, and memory CD4 T cells, and most TCR clonotypes existed as singletons, underscoring the enormous baseline diversity maintained even without acute immune challenge.

A key technical contribution came from the pig-specific V(D)J primers designed for the study. Compared with previously published porcine repertoire datasets, the strategy detected substantially more heavy-chain V, light-chain V, and light-chain J immunoglobulin alleles, offering improved sensitivity and broader coverage of porcine antibody diversity. The authors caution that the pooled-sample design cannot assess individual variability, that cell annotations lack independent orthogonal validation, and that antigen specificity was not directly tested. Even so, the atlas stands as a foundational reference for the healthy porcine adaptive immune system, with immediate relevance for vaccine design, infectious disease research, breeding for disease resistance, and the growing use of pigs as translational models in biomedical science.

Subject of Research: Single-cell profiling of T cell and B cell receptor V(D)J immune repertoires across tissues in healthy pigs

Article Title: A single-cell profile of the porcine immune repertoire: concurrent profiling of T cell receptor and B cell receptor V(D)J sequences in health

Article References: Zhang, H., Zhang, Q., Zhang, H., Wang, P., Geng, R., Pan, R., Li, C., Shi, F., Liu, J., Wu, Y., & Cao, Y. (2026). A single-cell profile of the porcine immune repertoire: concurrent profiling of T cell receptor and B cell receptor V(D)J sequences in health. Advanced Biotechnology, 4(4), Article 38. https://doi.org/10.1007/s44307-026-00139-2

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00139-2

Keywords: single-cell RNA sequencing, V(D)J recombination, immune repertoire, T cell receptor, B cell receptor, porcine immunology, CDR3, clonotype sharing, plasma cells, DLY piglets, immunoglobulin isotypes, veterinary biotechnology

The study builds on earlier work by the same group, which had identified SARS-CoV-2 antigens showing both sequence and conformational homology to tumor-associated antigens, the molecular flags that tumors display on their surfaces and that the immune system can, in principle, attack. Cross-reactive T cells had already been detected in people who had either been infected with SARS-CoV-2 or vaccinated with the BNT162b2 mRNA vaccine. What remained unknown was the fine structure of that cross-reactivity: which T cell receptor genes were involved, what the hypervariable recognition loops looked like, and whether the same receptor architectures could be elicited by both the viral and the tumor-derived peptide. The new study set out to answer those questions directly.

To do so, the researchers selected a matched pair of epitopes presented by the same class of major histocompatibility complex molecules. The viral peptide, LLLDDFVEI, comes from a SARS-CoV-2 antigen, while its tumor counterpart, LLLDDLLVS, is derived from PRDX5, a tumor-associated antigen. The two nine-amino-acid sequences differ by only two residues, and both substitutions are conservative, meaning the overall shape and chemical character of the peptides are largely preserved. When processed and displayed on the cell surface in the peptide–MHC complex, the two epitopes present a sufficiently similar molecular surface that a single T cell receptor can plausibly engage both — the defining premise of molecular mimicry.

The experimental design was deliberately simple and controlled. Peripheral blood mononuclear cells were obtained from five healthy donors and cultured in the laboratory for ten days, during which the cells were stimulated every three days with 10 micrograms of one or the other of the two peptides. This ex vivo priming allowed rare cross-reactive T cells to expand to numbers that could be reliably detected and characterized. After the stimulation period, the researchers performed single-cell RNA sequencing paired with T cell receptor sequencing, a technique that captures both the transcriptomic identity of each cell and the full nucleotide sequence of its receptor’s alpha and beta chains, including the crucial CDR3 regions that make direct contact with the peptide–MHC complex.

The results, focused on CD8-positive effector T cells, revealed a striking pattern. In each donor, treatment with either epitope amplified or newly induced a small, reproducible set of TRAV and TRBV gene segments — the variable regions of the receptor’s alpha and beta chains — together with characteristic CDR3α and CDR3β amino acid motifs. Critically, the very same clonotypes appeared in both stimulation conditions: T cells expanded by the viral peptide carried the same receptor signatures as those expanded by the tumor peptide. These signatures were strictly individual, differing from donor to donor, and none of the identified motifs matched any entry in publicly available T cell receptor repositories, underscoring how personal the anti-viral and, by extension, the cross-reactive anti-tumor repertoire can be.

The cross-reactive clones were not confined to the effector compartment. The researchers found the identical clonotypes within the CD8-positive proliferating subset, indicating that both epitopes drove the same cells into a highly activated, dividing state. In immunological terms, this plasticity matters: it suggests that exposure to the viral epitope does not merely expand a narrow, terminally differentiated population but recruits versatile effector cells capable of further proliferation and functional diversification — properties desirable in a vaccine-elicited response intended to attack tumor cells presenting the mimic antigen in vivo.

To test whether the shared clonotypes reflected genuine structural cross-recognition rather than coincidental co-expansion, the team performed conformational prediction analyses of the peptide–MHC–TCR complexes. The modeled structures showed a perfect structural overlap between complexes built on the viral epitope and those built on the tumor epitope. In other words, when the same receptor docks onto either peptide presented by MHC, the geometry of the interaction is essentially indistinguishable. This structural convergence provides a mechanistic explanation for the functional cross-reaction observed in the cell cultures and elevates the finding from a correlational observation to a validated molecular event.

The authors emphasize the functional significance of the result in light of a well-known feature of T cell biology: degeneracy. A single T cell receptor can often recognize multiple different peptides, and a single epitope can be recognized by many different receptors. Given this inherent promiscuity, finding identical CDR3αβ motifs elicited by two homologous but non-identical epitopes is, as the researchers describe it, of the highest functional relevance. It demonstrates that the mimicry between the SARS-CoV-2 peptide and the PRDX5-derived tumor peptide is tight enough to select for the same receptor solutions across independent stimulation conditions and across genetically distinct donors’ repertoires.

The translational implication is the most consequential part of the work. Tumor-associated antigens are self antigens, and the immune system is generally tolerant of them, which has long hampered therapeutic cancer vaccines: self-derived peptides tend to be weak immunogens that expand low-affinity or exhausted T cells, if they expand anything at all. Microbial epitopes, by contrast, are foreign, and the immune system responds to them vigorously. The study’s results provide, for the first time, a clear experimental validation that microbial epitopes mimicking tumor-associated antigens can be used to develop off-the-shelf preventive or therapeutic vaccine formulations. A vaccine built on a viral mimic would exploit the immune system’s readiness to mount strong responses against non-self sequences while redirecting the resulting effector cells, through cross-reactivity, against tumor cells displaying the homologous self antigen.

Several caveats and open questions remain before such a strategy reaches the clinic. The study involved five healthy donors and a single epitope pair, so the breadth of the mimicry effect across other tumor antigens, HLA backgrounds, and patient populations will need to be established. Whether vaccine-elicited cross-reactive T cells can actually infiltrate tumors and mediate clinically meaningful anti-tumor activity in vivo is the decisive next test, and the risk that broadly cross-reactive responses could target healthy tissues expressing PRDX5 must be carefully evaluated. The work was funded by the Italian Ministry of Health through institutional research programs and a PNRR project on molecular mimicry to improve liver cancer immunotherapy, signaling that hepatocellular carcinoma is one intended application. Even with those qualifications, the study marks a milestone: it converts molecular mimicry from an epidemiological curiosity — the observation that some infections correlate with altered cancer risk — into a precisely characterized receptor-level mechanism that can be engineered on purpose. If follow-up studies confirm that viral-mimic vaccines can reliably expand functional, tumor-directed CD8 T cells, the pandemic coronavirus that reshaped global health may also leave behind an unexpected gift for oncology.

Subject of Research: Cross-reactivity between SARS-CoV-2-specific T cells and tumor-associated antigens via molecular mimicry

Article Title: SARS-CoV-2-specific T cells cross-react with tumor-associated antigens via molecular mimicry

Article References: Ragone, C., Mauriello, A., Cavalluzzo, B., Mangano, S., Cembrola, B., Ciotola, N., Tagliamonte, M., & Buonaguro, L. (2026). SARS-CoV-2-specific T cells cross-react with tumor-associated antigens via molecular mimicry. Journal of Translational Medicine, 24(1), Article 1179. https://doi.org/10.1186/s12967-026-08905-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08905-5

Keywords: SARS-CoV-2, molecular mimicry, tumor-associated antigens, T cell receptor, cross-reactivity, cancer vaccine, CD8 T cells, single-cell RNA sequencing, PRDX5, immunotherapy, epitopes, Journal of Translational Medicine

The study, published in the British Journal of Cancer, analyzed tumor specimens from 56 patients with newly diagnosed IDH-wildtype glioblastoma, the most common and most lethal molecular subtype of the disease. Rather than assuming all tumors look alike immunologically, the researchers first screened their cohort to identify cases with prominent intratumoral T-cell infiltration, a feature that only a fraction of glioblastomas display. In those T-cell-rich cases, they isolated CD3-positive, CD8-positive, CD4-negative cytotoxic T cells, the immune cells theoretically capable of killing tumor cells directly, and subjected them to single-cell RNA sequencing paired with T-cell receptor sequencing, a combination that reveals both what each cell is doing and what antigen specificity its receptor encodes.

The single-cell analysis produced a striking and consistent picture. Unsupervised clustering of the transcriptional data identified a dominant population of tumor-infiltrating lymphocytes defined by strong expression of exhaustion markers, with the checkpoint molecule LAG3 standing out as the most prominent. Exhaustion is a dysfunctional state that T cells enter after chronic antigen stimulation, in which they retain tumor recognition but lose much of their killing capacity. Critically, these exhausted cells also showed high T-cell receptor clonality, meaning the same receptor sequences appeared repeatedly across many cells. Clonal expansion of this kind is a classic hallmark of antigen-driven proliferation: it indicates that a specific stimulus, very plausibly tumor antigen, drove these cells to multiply within the tumor microenvironment.

To test whether this pattern was unique to their cohort or a general feature of glioblastoma, the team integrated their dataset with publicly available single-cell data from glioblastoma tumor-infiltrating lymphocytes and, as a comparative benchmark, with datasets from lung cancer TILs and malignant pleural effusions. The comparison revealed meaningful differences. Levels of LAG3 and of CXCL13, a chemokine that has emerged in recent years as a marker of tumor-reactive T cells in multiple cancer types, were significantly higher in the T-cell-rich glioblastoma subset from the Aichi Cancer Center cohort than in the public glioblastoma dataset. This suggests that T-cell infiltration in glioblastoma is not a uniform phenomenon but varies substantially between patients, and that the most infiltrated tumors contain a particularly pronounced exhausted, potentially tumor-specific compartment.

The most consequential step came next. The researchers applied an artificial intelligence-based prediction algorithm, developed with collaborators at NEC OncoImmunity, that estimates which T-cell receptors are likely to recognize tumor antigens based on sequence features and transcriptional context. When the algorithm was run across the datasets, it predicted that the T-cell-rich glioblastoma subset harbored a markedly higher proportion of potentially reactive T cells than either the public glioblastoma dataset or the lung cancer comparator samples. In other words, the exhausted, clonally expanded cells dominating these tumors are not merely bystanders or nonspecific inflammatory recruits; a substantial fraction of them may be genuinely tumor-reactive, held in check by their exhausted state.

These findings carry two major therapeutic implications. The first concerns LAG3, which has become one of the most closely watched immune checkpoint targets after PD-1 and CTLA-4. LAG3-blocking antibodies are already in late-stage clinical development for other cancers, and the new data provide a mechanistic rationale for testing LAG3-targeted approaches in glioblastoma, particularly in patients whose tumors show dense T-cell infiltration. If the potentially reactive T cells in these tumors are suppressed largely through LAG3-mediated inhibition, releasing that brake could reactivate a T-cell army that is already present and antigen-primed, a fundamentally different situation from trying to prime a response that does not exist.

The second implication involves antigen-specific immunotherapy, including personalized neoantigen vaccines and adoptive cell transfer. Previous work, such as the landmark neoantigen vaccine trial in glioblastoma led by researchers at Dana-Farber Cancer Institute, demonstrated that vaccine-induced T cells can traffic into these brain tumors, and other studies have shown that microbial peptides and aberrantly spliced tumor RNAs can generate antigens recognized by infiltrating lymphocytes. The new study adds a crucial piece to this puzzle by showing that in a subset of patients, the raw material for such approaches, clonally expanded, potentially tumor-reactive CD8 T cells, is already abundant. Identifying which patients fall into this T-cell-rich category could allow clinicians to select those most likely to benefit from vaccines, engineered T-cell therapies, or checkpoint blockade, moving glioblastoma immunotherapy toward a biomarker-driven strategy rather than a one-size-fits-all failure.

The study also refines the scientific understanding of T-cell exhaustion in brain tumors. Earlier single-cell analyses had described glioblastoma-infiltrating CD8 T cells as severely exhausted and had identified inhibitory receptors such as CD161 on glioma-infiltrating T cells, while other work characterized the dominant population as clonally expanded GZMK-positive effector cells. The new data reconcile these views by showing that exhaustion signatures in glioblastoma are not homogeneous: within the exhausted compartment, the clonally expanded, LAG3-high, CXCL13-positive subset is the one most likely to contain tumor-reactive cells. Distinguishing this potentially reactive exhausted state from generic dysfunction could guide the design of combination therapies that reinvigorate the right cells rather than broadly activating all T cells in the brain, where uncontrolled inflammation carries serious risks.

Important caveats remain. The prediction algorithm identifies candidate reactive T-cell receptors, but reactivity must ultimately be confirmed experimentally by identifying the antigens they recognize, and the proportion of truly tumor-specific cells among the predicted candidates is unknown. The T-cell-rich phenotype also applies to only a subset of the 56 patients studied, so the findings may not generalize to all glioblastomas. Nevertheless, the study provides a concrete foundation for two concrete therapeutic directions: antigen-specific approaches built on the T-cell receptors found in these tumors, and LAG-3-targeted immunotherapy aimed at releasing the brakes on cells that appear primed and waiting. For a disease whose median survival has barely moved in decades, the discovery that some glioblastomas already contain a recognizable, targetable immune response is a reason for cautious optimism, and a roadmap for the trials that must now follow.

Subject of Research: CD8+ tumor-infiltrating lymphocyte exhaustion signatures and potential tumor reactivity in glioblastoma

Article Title: Abundant CD8+ tumor-infiltrating lymphocytes in glioblastoma harbor distinct exhaustion signatures in potentially reactive subsets

Article References: Okamoto, T., Mizuta, R., Demachi-Okamura, A., Muraoka, D., Fukushima, Y., Ishihara, H., Sun, Y., Wang, Y., Nishida, R., Sasaki, E., Masago, K., Onoguchi, K., Tanaka, Y., Yamashita, Y., Stratford, R., Clancy, T., Muto, O., Tan, C. L., Otani, Y., … Matsushita, H. (2026). Abundant CD8+ tumor-infiltrating lymphocytes in glioblastoma harbor distinct exhaustion signatures in potentially reactive subsets. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03619-3

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03619-3

Keywords: glioblastoma, CD8 T cells, tumor-infiltrating lymphocytes, T-cell exhaustion, LAG3, CXCL13, single-cell RNA sequencing, T-cell receptor, immunotherapy, neoantigen, checkpoint inhibitors, brain cancer

The focus of the new work is a population of immune cells known as gamma delta T cells, a specialist lineage that patrols tissues throughout the body, including the skin and the gut, on the lookout for damage, infection and cancer. Unlike the more familiar alpha beta T cells that dominate adaptive immunity, gamma delta T cells have long been regarded as immunological hybrids. They can detect signs of cellular stress and dysregulation without needing the lengthy priming that conventional adaptive responses require, and they can act rapidly against abnormal cells. That combination of speed and broad reactivity has made them one of the most promising candidates for next-generation cancer immunotherapies, and scores of clinical trials are currently underway to harness their potential.

Yet a fundamental question has lingered beneath all of that clinical enthusiasm. Like other adaptive immune cells, gamma delta T cells carry signature receptors on their surface, the products of the same genetic rearrangement machinery that generates the vast receptor repertoires of conventional T and B cells. During development, these so-called T cell receptors help shape how gamma delta T cells mature, where they settle in the body and how prepared they are to respond to particular kinds of stress. But many researchers had assumed that once the cells were mature and deployed into tissues, the receptor’s job was essentially done. If gamma delta T cells respond so rapidly and so innately, surely their adaptive receptor could not be involved in real time?

Adrian Hayday, Principal Group Leader at the Francis Crick Institute who has studied gamma delta T cells for more than four decades, teamed up with Miguel Munoz-Ruiz, a former postdoc in his laboratory who now leads his own research programme at Complutense University of Madrid, to answer that question definitively. “There is a lot of interest and progress in using gamma delta T cells in cancer immunotherapies, or even other types of immune treatment, because they can recognise any kind of dysregulation and act quickly,” Hayday explains. “But if we are going to use them clinically, we need to understand what underpins that rapid response.”

The two teams designed a series of experiments to ask what happens when the gamma delta T cell receptor is removed from mature cells that are already stationed in tissues. In mice engineered so that the receptor could be deleted from selected populations of resident gamma delta T cells, the researchers, working with Nicolas Veland in Hayday’s lab and Bethania Garcia-Cassani in Munoz-Ruiz’s team, observed that the receptor was essential to the cells’ continuing tissue surveillance function. This was a striking result. The cells did not simply carry on with their innate-like patrol work once the receptor was gone; instead, their core identity as sentinels began to unravel.

When the receptor was removed, the gamma delta T cells remained physically present in the tissues, but their behaviour changed markedly. The researchers documented alterations in the activity of genes involved in activation, tissue surveillance and communication with other immune cells. Perhaps most tellingly, they also saw disruption to receptors associated with innate immune responses, the very molecular machinery that was supposed to operate independently of adaptive recognition. In other words, pulling out the adaptive receptor did not leave the innate program intact; it compromised it.

To determine whether the same principle holds in human cells, Veland undertook key parts of the experimental work in laboratory-grown human gamma delta T cells, using CRISPR gene-editing technology to disrupt a gene encoding part of the gamma delta T cell receptor. The result echoed the mouse findings closely. Removing the receptor altered gene activity and reduced the expression of several receptors associated with innate responses, indicating that the dependence on receptor signalling is not a quirk of the mouse immune system but a conserved feature of gamma delta T cell biology across species.

The consequences for cancer surveillance were equally significant. Across mouse models of both skin cancer and colorectal cancer, the loss of the gamma delta T cell receptor impaired the immune system’s ability to control tumour development. In further laboratory experiments, receptor-deficient human gamma delta T cells were less able to restrict the growth of melanoma and colorectal cancer cells. Taken together, these results demonstrate that the rapid, innate-like anti-tumour activity that makes gamma delta T cells so attractive for immunotherapy is not a receptor-independent property of the cells themselves; it depends, in real time, on the continuous signalling of their adaptive T cell receptor.

“This work came from a shared question that Adrian and I kept coming back to,” says Munoz-Ruiz. “If gamma delta T cells are so rapid and so innate-like, what is their receptor doing?” The answer, the teams have now shown, is that the receptor is doing a great deal. “We’ve shown that without receptor signalling, gamma delta T cells are much less able to carry out rapid tissue surveillance, showing that responses previously thought to be independent of adaptive immune recognition still rely on the gamma delta T cell receptor in real time.” The finding reframes the receptor not as a developmental scaffold that can be discarded after maturation, but as an ongoing operational requirement for the cells’ frontline duties.

For the growing field of gamma delta T cell therapy, the implications are immediate and practical. The findings suggest that gamma delta T cell treatments may depend on preserving or activating the receptor signal that helps these cells recognise and respond to damage and disease. Therapeutic strategies that expand or transfer gamma delta T cells without safeguarding their receptor function could, according to this new evidence, deliver cells that are present but functionally blunted. “These findings are incredibly important if we want those cells to attack tumours effectively,” Hayday adds. Beyond the clinic, the study points to what the researchers describe as a fundamental shift in how immune responses are understood. These cells defy the traditional classifications of immunity: an adaptive receptor being used as part of the innate immune response. That may, Hayday suggests, explain why gamma delta T cells have been conserved across many different species, offering an essential and unique form of surveillance that does not fit neatly into either category of the classical immune dichotomy.

Subject of Research: The role of gamma delta T cell receptors in rapid innate-like tissue surveillance and cancer immunosurveillance

Article Title: Immune cells defy textbook classifications

Article References: Immune cells defy textbook classifications. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: gamma delta T cells, innate immunity, adaptive immunity, T cell receptor, cancer immunotherapy, tissue surveillance, Francis Crick Institute, Nature, CRISPR, tumour immunology, immune cell receptors, immunosurveillance

The research team enrolled 206 pediatric patients diagnosed with mycoplasma pneumoniae pneumonia and compared their peripheral blood immune and inflammatory parameters across clinically defined subgroups, distinguishing macrolide-sensitive cases from severe disease. The comparisons revealed a clear inflammatory gradient. Children with severe mycoplasma pneumonia displayed significantly elevated white blood cell counts and markedly higher circulating levels of interleukin-6, a central pro-inflammatory cytokine that drives acute-phase responses and is often used as a marker of systemic inflammation. At the same time, these severe cases showed reduced proportions of monocytes, a shift that suggests alterations in innate immune cell dynamics as the disease escalates. Taken together, these findings confirm that severe pediatric mycoplasma pneumonia is accompanied by heightened systemic inflammation, providing clinicians with measurable correlates of disease severity that go beyond symptoms and imaging.

While the blood-based immune markers painted a picture of generalized inflammation, the heart of the study lay in its analysis of the T cell receptor beta chain, specifically the complementarity-determining region 3, or CDR3. This hypervariable loop sits at the very tip of the T cell receptor and makes direct contact with peptide antigens presented by major histocompatibility complex molecules. Because the CDR3 sequence is generated through a stochastic process of V, D and J gene segment recombination, joined by random nucleotide trimming and insertion at the junctions, each naive T cell carries a essentially unique CDR3 signature. When a pathogen invades, the handful of T cells whose receptors happen to recognize its antigens undergo clonal expansion, multiplying into large populations of identical sequences that can be detected by sequencing the repertoire. The composition of these expanded clones therefore serves as a molecular record of the antigenic encounters the immune system has experienced.

To capture this record, the researchers performed TCR beta CDR3 repertoire sequencing on peripheral blood samples from eight children with mycoplasma pneumoniae pneumonia and nine age-matched healthy controls. Although the sequencing cohort was modest in size, the bioinformatic analysis was comprehensive, examining repertoire clonality, diversity indices, V and J gene segment usage, CDR3 length distributions, recombination characteristics, and the presence of disease-associated high-frequency or shared clonotypes. The results showed that children with mycoplasma pneumonia had measurably reduced CDR3 diversity compared with healthy controls, a contraction of the overall repertoire that is consistent with a strong antigen-driven response in which a limited number of pathogen-specific clones expand and crowd out the diverse background of bystander T cells.

The clonal architecture itself was also transformed. In healthy individuals, the T cell pool is dominated by a vast number of small, rare clones, with only a sparse scattering of expanded sequences. In the mycoplasma pneumonia patients, the researchers observed a shift toward more medium and large clones, indicating that a substantial fraction of the circulating T cell population had been recruited into antigen-driven expansion. This oligoclonal skewing is a hallmark of active infection and mirrors patterns previously documented in viral infections and other inflammatory lung diseases. The degree of clonal expansion, quantified through measures of clonality, could in principle serve as a quantitative readout of the intensity of the adaptive immune response, potentially helping clinicians distinguish children mounting an effective response from those at risk of immunopathology.

Beyond clonality, the study uncovered striking differences in the genetic mechanics of receptor generation. The mycoplasma pneumonia group showed significant alterations in the usage frequencies of individual TRBV and TRBJ gene segments, the variable and joining elements that form the framework of the beta chain receptor. Certain V-J pairing combinations were overrepresented or underrepresented relative to controls, suggesting that the antigenic landscape presented by mycoplasma pneumoniae selects for receptors built from particular gene segments. The patients also exhibited increased CDR3 lengths, altered amino acid composition within the hypervariable loop, and enhanced V(D)J trimming and nucleotide insertion activity at the recombination junctions. These features imply that the receptors expanded during infection tend to be longer and more compositionally distinctive than average, a pattern that may reflect the structural requirements of recognizing mycoplasma-derived peptides or, alternatively, the recruitment of T cells activated by molecular mimicry.

Perhaps the most intriguing discovery emerged from the search for pathogen-associated clonotypes. The team identified several putative mycoplasma-associated CDR3 sequences that were either present at high frequency in patients or shared across multiple individuals, suggesting convergent recognition of common mycoplasma antigens. Remarkably, some of these expanded clones showed potential cross-reactivity with respiratory viruses, including influenza and Epstein-Barr virus. This observation carries significant immunological weight. Cross-reactive T cells, activated by one pathogen but capable of recognizing structurally similar epitopes from another, are increasingly appreciated as important players in heterologous immunity, the phenomenon by which prior infections shape responses to new ones. In the context of pediatric pneumonia, such cross-reactive expansions could influence disease severity, either by accelerating viral clearance or by contributing to the immune-mediated lung damage seen in severe mycoplasma cases.

The identification of candidate immune signatures also opens a practical avenue for clinical translation. If the disease-associated clonotypes and repertoire features documented here can be validated in larger cohorts, they could form the basis of diagnostic or prognostic tools. A sequencing-based assay that detects mycoplasma-associated T cell expansions might help confirm infection in cases where culture and serology are inconclusive, since mycoplasma is notoriously difficult to grow in the laboratory and antibody responses can be delayed or unreliable in young children. Repertoire clonality measures might additionally serve as biomarkers for monitoring host immune status over the course of treatment, flagging patients whose inflammatory trajectory is worsening before clinical deterioration becomes obvious. The authors suggest that these repertoire characteristics may reflect potential biomarkers for monitoring host immune status or infection-associated T cell responses in pediatric mycoplasma pneumonia.

Several caveats temper the immediate applicability of these findings. The sequencing arm of the study included only eight patients and nine controls, a sample size sufficient for generating hypotheses but insufficient for establishing robust clinical biomarkers. Longitudinal sampling, which would track how the repertoire evolves during infection and recovery, was not performed, and the cross-reactivity assignments to influenza and Epstein-Barr virus remain putative pending functional validation with antigen-specific stimulation assays. Future studies will need to expand patient numbers, incorporate follow-up time points, and pair repertoire data with antigen-specific T cell functional testing to confirm which clonotypes genuinely recognize mycoplasma antigens and which are bystanders or cross-reactive responders.

Nevertheless, the study represents a meaningful step toward bringing immune repertoire sequencing out of the research laboratory and into pediatric infectious disease medicine. By demonstrating that mycoplasma pneumoniae leaves a detectable and characteristic imprint on the TCR beta CDR3 landscape of infected children, the work establishes a framework for understanding the immunological heterogeneity that underlies the variable clinical course of this common infection. As sequencing costs continue to fall and analytical pipelines mature, the kind of repertoire profiling demonstrated here could eventually complement conventional laboratory tests, giving clinicians a dynamic view of the adaptive immune response as it unfolds. For a pathogen that has repeatedly proven difficult to detect and even more difficult to anticipate in terms of severity, the T cell receptor repertoire may prove to be one of the most informative windows yet into how the body fights back.

Subject of Research: T cell receptor repertoire changes in pediatric Mycoplasma pneumoniae pneumonia

Article Title: TCR β CDR3 repertoire profiling identifies pathogen-associated clonal expansions and candidate immune signatures in pediatric Mycoplasma pneumoniae pneumonia

Article References: Yuan, Y., Hui, L., Zhang, X., Liu, X., Yang, C., Xu, Y., Yao, X., Chen, Y., & Li, J. (2026). TCR β CDR3 repertoire profiling identifies pathogen-associated clonal expansions and candidate immune signatures in pediatric Mycoplasma pneumoniae pneumonia. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08992-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08992-4

Keywords: Mycoplasma pneumoniae, pediatric pneumonia, TCR repertoire, CDR3 diversity, high-throughput sequencing, T cell receptor, clonal expansion, interleukin-6, immune biomarkers, cross-reactivity, macrolide resistance, Journal of Translational Medicine

To understand why this matters, it helps to consider how T cells work. Each T cell in the body carries a receptor, known as a T-cell receptor or TCR, that recognizes fragments of foreign or abnormal proteins displayed on the surface of other cells. These fragments, called epitopes, are presented by human leukocyte antigen molecules, or HLAs, forming a peptide-HLA complex that the TCR must read with exquisite specificity. The portion of the receptor that does most of this reading is a loop called the CDR3 region on the beta chain of the receptor. Because the DNA sequences encoding CDR3 loops are assembled randomly during T-cell development, the human body can theoretically produce an astronomically large repertoire of receptors, allowing it to recognize nearly any pathogen or tumor marker it might encounter.

The problem for immunotherapy developers is that finding the right receptor for a given target is extraordinarily difficult. When a patient’s tumor displays a particular peptide on its HLA molecules, researchers want to identify or engineer TCRs that will bind that peptide-HLA complex specifically, so that engineered T cells can home in on the cancer. Today, that process depends heavily on laborious and expensive experimental screening: collecting T cells that happen to respond to the target, sequencing their receptors, cloning candidates, and testing them one by one. The sheer scale of possible CDR3 sequences means that even large screens sample only a vanishingly small corner of the search space, and promising receptors may be missed entirely. This bottleneck is precisely what the ERTransformer was designed to relieve.

The architecture of the new model rests on two pre-trained transformer networks, the same class of deep learning architecture that underlies modern large language models. The first component, EpitopeBERT, was trained on approximately 1.9 million epitope sequences, allowing it to internalize the statistical grammar of the peptide fragments that the immune system encounters. The second, ReceptorBERT, was trained on roughly 33.1 million TCR sequences, giving it a deep understanding of the structural and compositional constraints that govern which receptor loops are biologically plausible. By combining these two pre-trained encoders, ERTransformer can be conditioned on a specific epitope and then generate candidate beta-chain CDR3 sequences that are plausible as receptors while being directed toward that particular target, much as a language model conditioned on a topic generates relevant text.

Conditioning is the crucial trick. A generative model trained only on receptor sequences could produce endless plausible-looking CDR3 loops, but with no guarantee that any of them would recognize the intended target. By feeding epitope information into the generation process, the researchers steered the model so that its outputs were biased toward receptors relevant to a defined peptide-HLA context. This epitope-conditioned generation transforms the model from a random sequence generator into a targeted design tool, capable of expanding and prioritizing candidate receptors for downstream experimental screening in defined peptide-HLA and TCR-chain contexts, as the authors describe in their conclusions.

To demonstrate the capability, the team put the model through a concrete test. They selected five epitopes for which natural TCRs are already known, and asked ERTransformer to generate 1,000 candidate beta-chain CDR3 sequences for each one. The resulting pool of 5,000 artificial sequences was then analyzed for how well it satisfied the statistical expectations of real receptor biology. The generated candidates showed low sequence similarity to natural TCR beta chains, meaning the model was not simply memorizing and copying receptors from its training data, while at the same time retaining plausible CDR3 lengths, realistic amino-acid composition, and the conservative substitution patterns characteristic of genuine receptor loops. In other words, the artificial sequences looked novel but not alien, a balance that is notoriously hard to strike in generative protein design.

Novelty alone, however, proves nothing in immunology. A receptor sequence that looks plausible on paper may fail to fold, fail to bind, or bind the wrong things entirely. That is why the most striking part of the study is its wet-laboratory validation. The researchers selected a subset of the artificial TCRs and tested them experimentally using flow cytometry in defined TCR and peptide-HLA contexts, measuring the degree of T-cell activation each engineered receptor produced. The results exceeded what many in the field might have expected: the level of T-cell activation induced by the selected artificial receptors was either comparable to or even surpassed that of the natural receptors specific for the same epitopes. Synthetic sequences, dreamed up by a transformer model and never evolved in any organism’s thymus, could genuinely do the job.

The implications of that finding ripple across several areas of medicine. TCR-based immunotherapies, in which a patient’s T cells are engineered to express a receptor targeting a tumor-associated peptide, represent one of the most promising frontiers in cancer treatment. But their development has been constrained by the difficulty of sourcing high-affinity, specific receptors, particularly for targets where natural T cells respond weakly or not at all. A generative model that can propose thousands of candidate receptors for a defined target, each statistically vetted for plausibility, could dramatically expand the starting pool for screening and increase the odds of finding a receptor with the right combination of potency and specificity. The authors position ERTransformer explicitly as a tool to expand and prioritize candidates for downstream experimental screening, not as a replacement for experimentation, but as a way to make that experimentation far more efficient.

The study also illustrates a broader trend in computational biology: the power of pre-training on massive unlabeled datasets before fine-tuning on specific tasks. Just as language models learn general grammar from billions of sentences before being adapted to translation or summarization, EpitopeBERT and ReceptorBERT learned the general statistics of epitopes and receptors from millions of sequences before being combined for epitope-conditioned generation. The supplementary analyses accompanying the paper, including leakage-controlled evaluations, length distribution comparisons, and diversity and novelty analyses, suggest the team took seriously the methodological pitfalls that can make generative models appear better than they are, such as accidentally training on sequences that also appear in the test set.

Published as open access on 2 September 2026 in Genome Biology, with the work supported in part by the National Natural Science Foundation of China, the study arrives at a moment when generative artificial intelligence is reshaping protein science at large. From protein structure prediction to de novo enzyme design, machine learning models are increasingly proposing molecules that experimenters then confirm in the lab. The ERTransformer extends that paradigm to the adaptive immune system, one of the most complex and personalized molecular landscapes in biology. If the approach generalizes beyond the five epitopes tested here, the painstaking hunt for therapeutic T-cell receptors could become a collaboration between vast pre-trained models and targeted experiments, with algorithms proposing and laboratories verifying. For patients waiting on the next generation of engineered T-cell therapies, that collaboration could mean the difference between candidates found by chance and candidates found by design.

Subject of Research: Epitope-conditioned generative AI for designing T-cell receptor beta-chain CDR3 sequences for immunotherapy

Article Title: Epitope-conditioned generation of T-cell receptor β-chain CDR3 candidates using a pre-trained transformer model

Article References: Yang, J., He, B., Guan, L., Chen, S., Zhao, Y., Jiang, F., Wang, Z., Guo, Y., Xu, Z., Yuan, B., Song, J., Zhang, Q., Li, T., & Yao, J. (2026). Epitope-conditioned generation of T-cell receptor β-chain CDR3 candidates using a pre-trained transformer model. Genome Biology. https://doi.org/10.1186/s13059-026-04266-w

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04266-w

Keywords: T-cell receptor, CDR3, epitope, transformer model, generative AI, immunotherapy, peptide-HLA, protein design, flow cytometry, pre-trained language model, Genome Biology, T-cell activation